on December 14, 2006
Published online before print December 14, 2006, doi: 10.1161/01.ATV.0000255580.73689.8e
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on September 23, 2006
Accepted on November 30, 2006
Improving Prediction of Ischemic Cardiovascular Disease in the General Population Using Apolipoprotein B. The Copenhagen City Heart Study
Marianne Benn ;
From the Department of Clinical Biochemistry (M.B., A.T.-H.), Rigshospitalet, Copenhagen University Hospital; Department of Clinical Biochemistry (M.B., B.G.N.), Herlev University Hospital; The Copenhagen City Heart Study (B.G.N., G.B., A.T.-H.), Bispebjerg University Hospital, University of Copenhagen, Denmark.
* To whom correspondence should be addressed. E-mail: at-h{at}rh.dk.
Background--Apolipoprotein B (apoB) levels predict fatal myocardial infarction. Whether apoB also predicts nonfatal ischemic cardiovascular events is unclear. We tested the following hypotheses: apoB predicts ischemic cardiovascular events, and apoB is a better predictor of ischemic cardiovascular events than low-density lipoprotein cholesterol.
Methods and Results--We studied 9231 asymptomatic women and men from the Danish general population followed prospectively for 8 years and observed the following incident events: ischemic heart disease 591, myocardial infarction 278, ischemic cerebrovascular disease 313, ischemic stroke 229, and any ischemic cardiovascular event 807. Women with apoB in the upper versus the lower tertile had hazard ratios for ischemic heart disease of 1.8 (1.2 to 2.5), for myocardial infarction 2.6 (1.4 to 4.7), and for any ischemic cardiovascular event 1.8 (1.3 to 2.3), and men had hazard ratios for ischemic heart disease of 1.9 (1.5 to 2.6), for myocardial infarction 2.4 (1.5 to 3.6), and for any ischemic cardiovascular event 1.6 (1.3 to 2.1). Women had similar hazard ratios for ischemic cerebrovascular disease and ischemic stroke. ApoB had a higher predictive ability than low-density lipoprotein cholesterol in the prediction of ischemic heart disease, myocardial infarction, any ischemic cardiovascular event, and any nonfatal ischemic cardiovascular event in both genders (P=0.03 to <0.001). Finally, in smokers older than 60 years with systolic blood pressure >160 mm Hg, apoB contributed 11% in women and 15% in men to the increase in absolute 10-year risk from the lower to the upper apoB tertile.
Conclusion--ApoB predicts ischemic cardiovascular events in both genders, and is better than low-density lipoprotein cholesterol in this respect. We suggest that prediction of future ischemic cardiovascular events could be improved by measuring apoB.
Key words: apolipoproteins • atherosclerosis • cardiovascular diseases • lipids • lipoproteins
This article has been cited by other articles:
 |
|
 |
|
  Y. Henkin Re-Evaluating Therapeutic Target Goals for Statin-Treated Patients: Time for Revolutionary Changes? J. Am. Coll. Cardiol., August 19, 2008; 52(8): 633 - 635. [Full Text] [PDF]
|
|
|
|
 |
|
 J. J.P. Kastelein, W. A. van der Steeg, I. Holme, M. Gaffney, N. B. Cater, P. Barter, P. Deedwania, A. G. Olsson, S. M. Boekholdt, D. A. Demicco, et al. Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment Circulation, June 10, 2008; 117(23): 3002 - 3009. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Benn, M. C. A. Stene, B. G. Nordestgaard, G. B. Jensen, R. Steffensen, and A. Tybjaerg-Hansen Common and Rare Alleles in Apolipoprotein B Contribute to Plasma Levels of Low-Density Lipoprotein Cholesterol in the General Population J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 1038 - 1045. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. O. Mudd, B. A. Borlaug, P. V. Johnston, B. G. Kral, R. Rouf, R. S. Blumenthal, and P. O. Kwiterovich Jr Beyond Low-Density Lipoprotein Cholesterol: Defining the Role of Low-Density Lipoprotein Heterogeneity in Coronary Artery Disease J. Am. Coll. Cardiol., October 30, 2007; 50(18): 1735 - 1741. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Benn, B. G. Nordestgaard, J. S. Jensen, and A. Tybjaerg-Hansen Polymorphisms in Apolipoprotein B and Risk of Ischemic Stroke J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3611 - 3617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Ingelsson, E. J. Schaefer, J. H. Contois, J. R. McNamara, L. Sullivan, M. J. Keyes, M. J. Pencina, C. Schoonmaker, P. W. F. Wilson, R. B. D'Agostino, et al. Clinical Utility of Different Lipid Measures for Prediction of Coronary Heart Disease in Men and Women JAMA, August 15, 2007; 298(7): 776 - 785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. G. Nordestgaard, M. Benn, P. Schnohr, and A. Tybjaerg-Hansen Nonfasting Triglycerides and Risk of Myocardial Infarction, Ischemic Heart Disease, and Death in Men and Women JAMA, July 18, 2007; 298(3): 299 - 308. [Abstract] [Full Text] [PDF]
|
|